Capricor shares rise ahead of FDA Deramiocel decision after rough week
Capricor Therapeutics shares gained 5% on Friday ahead of an FDA decision on Deramiocel expected this weekend, Stocktwits reported.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Stocktwits, shares of Capricor Therapeutics (CAPR) climbed 5% on Friday even as the broader market weakened. Investors are waiting for the U.S. Food and Drug Administration's ruling on Deramiocel, a therapy for Duchenne muscular dystrophy. The agency's action date is November 22. The company wants the drug approved to preserve upper-limb function in patients older than nine.
Despite Friday's gain, the stock was on track for a weekly decline of about 17%. The FDA earlier rejected the first application for lack of substantial evidence, and an advisory committee voted against the drug for cardiomyopathy. Capricor then filed more data and proposed a narrower label. Analysts are split: Oppenheimer expects approval, while H.C. Wainwright sees only a small chance of it.
why it matters
For investors, the key driver is the FDA's decision, which will directly shape the drug's prospects and the stock's direction. Management says the arbitration with partner NS Pharma should not delay patient access if the drug is approved.
market impact
Capricor: the FDA decision on Deramiocel will set the stock's next move.
tags
instruments
on polymarket
sources
- CAPR Stock Gains Ahead Of Weekend FDA Deramiocel Decision After Rough Week — Stocktwits, 20 November 2026 at 20:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗